NY-ESTÉE-LAUDER
The Estée Lauder Companies Inc. (NYSE: EL) today announced that Tracey T. Travis, Executive Vice President and Chief Financial Officer, has decided to retire, effective June 30, 2025, after more than twelve years of exemplary leadership and service at the company. A successor for the CFO role has been identified and will be named in the coming weeks. Tracey will work closely with this person to ensure a smooth and successful transition.
“Tracey has been an invaluable business partner and a trusted advisor to me, our executives and Board of Directors, as well as a mentor and role model to many across our organization,” said Fabrizio Freda, President and Chief Executive Officer. “She has built and led a robust, integrated Global Finance & Strategy organization that has served as a valued business partner across the company and has helped to optimize delivery of our financial plans. Her financial acumen, discipline, and operational excellence have been essential to our company’s growth, and so many areas of our organization have her valuable imprint on them.”
Since joining The Estée Lauder Companies (ELC), Tracey has led the company’s Global Finance, Accounting, Tax, Treasury, Investor Relations, Information Technology, and Strategy and New Business Development organizations. Tracey has also co-led the company’s Global Value Council and served as a member of the Executive Leadership Team and the Investment Development Committee. Tracey has also been a respected and engaging leader in her extensive work with our global investor community.
Under her guidance, the company has enhanced its financial strength and flexibility, enabling us to further invest in our long-term growth drivers, such as innovation, digital transformation, emerging markets, talent development, and M&A strategy. Additionally, Tracey has played a pivotal role in leading and advancing the financial profile of our global brand portfolio.
Over the last twelve years, Tracey built a robust, integrated Global Finance & Strategy (F&S) organization at ELC that serves as a valued business partner across the company, with a particular focus on cultivating talent across the organization to bring new perspectives to the finance function. Under her leadership, F&S has provided financial guidance throughout the enterprise while maximizing business and transformational opportunities, optimizing the capital structure, and supporting brand growth strategies and cash management. Tracey leaves the F&S function a transformed organization.
Together with ELC’s senior leadership, Tracey has deeply embedded the company’s corporate strategy throughout the organization, solidifying core planning processes with an emphasis on executional excellence. Working alongside senior leadership, Tracey and her team have implemented and driven a progressive end-to-end M&A strategy and value-driven empowerment and integration, including many important strategic acquisitions and investments such as DECIEM and TOM FORD. Tracey has also led the New Incubation Ventures (NIV) team to enable the sourcing, building, and growth of the brands and business models of tomorrow.
Tracey has helped further improve and elevate the company’s Information Technology function, strengthening its competitive edge through investments in areas such as digital tech centers around the world, embodying ELC’s global approach to technology management and innovation and enhancing the diversity of its capabilities. Tracey also served as an instrumental leader in establishing the company’s shared services capability to support the business and its growth.
Tracey played a critical role in strengthening talent development and engagement by developing and growing ELC’s Finance & Strategy Leadership Development Program (FASLEAP), and guiding the function’s approach to identifying, training, and placing top talent. Tracey has also been a committed Global Executive Sponsor of the Women’s Leadership Network (WLN) employee resource group (ERG), where she helped further a culture of recognizing women as pioneers in the beauty industry and highlighting their creativity and ingenuity in shaping trends and redefining standards. She has been a passionate advocate for the company’s efforts across philanthropy, citizenship and sustainability, and inclusion, diversity and equity, including by championing initiatives to advance racial equity and representation within the company and the beauty industry.
“An inspiring and visionary leader, Tracey has been deeply committed to exemplifying our values throughout her years of dedicated service to our company,” said William P. Lauder, Executive Chairman. “Tracey has had a remarkable impact on driving our business forward by leading our portfolio strategy, but also by developing our talent, cultivating a culture of inclusion and continued learning, and advancing initiatives to foster a more diverse and equitable workplace and marketplace.”
Tracey has been honored with numerous industry awards and accolades throughout her distinguished career. She received a Best CFO award by Institutional Investor magazine, was recognized as one of the “Top 100 African Americans in Corporate America,” as well as “The Most Powerful Women in Corporate America” by Black Enterprise magazine. In 2019, she was honored with an Achiever Award by Cosmetic Executive Women. Tracey currently serves as a director on the Board of Accenture PLC and the Board of Meta Platforms Inc. (formerly, Facebook).
ABOUT THE ESTÉE LAUDER COMPANIES
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
For more information, visit www.elcompanies.com.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711879987/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
